Shibo Jiang
Fudan University, China
Biography
Shibo Jiang's major research interest is to develop antiviral drugs, microbicides, and vaccines against HIV, HPV, influenza virus, SARS-CoV, MERS-CoV, Ebola virus and Zika virus. He has pioneered the studies on development of anti-HIV microbicides for prevention of sexual transmission of HIV. He discovered the first highly potent anti-HIV C-peptide and his patent were licensed to Trimeris for developing the first peptide anti-HIV drug, T-20 (Enfuvirtide, Fuzeon). In collaboration with Shanxi Jinbo Biomedicine Co., Ltd., he has successfully developed an anti-HPV bioproduct, JB-01, for controlling HPV infection and reducing morbidity of cervical cancer, which was approved for clinical use in more than 500 hospitals in China. He has published 374 peer-reviewed SCI papers with >11,000 citations. He has applied for 26 US patents (18 of them were issued), and 17 Chinese and PCT patents (5 of them were issued), and given more than 190 oral presentations at international conferences, academic institutions and pharmaceutical companies in more than 30 countries.
Abstract
Abstract : A chemically modified milk protein for preventing HIV sexual transmission and treating HPV infection